Koltun W A, Bloomer M M, Colony P, Kauffman G L
Department of Surgery, Pennyslvania State University, College of Medicine, Milton S Hershey Medical Center, Hershey 17033-0850, USA.
Gut. 1996 Aug;39(2):291-8. doi: 10.1136/gut.39.2.291.
BACKGROUND/AIMS: The study of graft versus host disease of the intestine has significant clinical relevance and may also be a model for other immune mediated intestinal diseases. There presently is no simple non-invasive test that can be used to evaluate graft versus host disease induced intestinal injury in humans or animal models. This study tested the hypothesis that graft versus host disease leads to an increase in host bowel permeability as assessed by the relative urinary excretion of orally administered lactulose and rhamnose.
The urinary excretion ratio of orally administered lactulose and rhamnose was determined daily for two weeks in (Lewis x Brown-Norway) F1 rats with graft versus host disease caused by either the transplantation of parental (Lewis) small bowel or the intraperitoneal injection of parental (Lewis) splenic lymphocytes.
Significant twofold to fourfold increases in the lactulose to rhamnose ratio were seen in both small bowel transplant and splenic lymphocyte transfer animals suffering from graft versus host disease during the second postoperative week. This effect occurred sooner in small bowel transplant than in splenic lymphocyte transfer animals (postoperative day 7 versus 11, respectively). The signs of graft versus host disease, including splenomegaly and altered intestinal mucosal architecture, as well as the increased lactulose to rhamnose ratio were significantly attenuated in small bowel transplant animals treated with cyclosporine A (10 mg/kg/day).
Graft versus host disease is associated with an increase in the lactulose to rhamnose clearance ratio reflecting an increase in host bowel permeability. This increase, along with the signs of systemic graft versus host disease, can be significantly ameliorated by cyclosporine A. The lactulose to rhamnose clearance ratio is a non-invasive technique that can be used to assess the intestinal effects of graft versus host disease and the associated increase in intestinal permeability.
背景/目的:肠道移植物抗宿主病的研究具有重要的临床意义,也可能是其他免疫介导性肠道疾病的模型。目前尚无简单的非侵入性检测方法可用于评估人类或动物模型中移植物抗宿主病所致的肠道损伤。本研究检验了以下假设:通过口服乳果糖和鼠李糖的相对尿排泄量评估,移植物抗宿主病会导致宿主肠通透性增加。
对因移植亲代(Lewis)小肠或腹腔注射亲代(Lewis)脾淋巴细胞而患移植物抗宿主病的(Lewis×Brown-Norway)F1大鼠,连续两周每日测定口服乳果糖和鼠李糖的尿排泄率。
在术后第二周,小肠移植和脾淋巴细胞转移的移植物抗宿主病动物中,乳果糖与鼠李糖的比率显著增加了两倍至四倍。小肠移植动物出现这种效应的时间比脾淋巴细胞转移动物更早(分别为术后第7天和第11天)。用环孢素A(10mg/kg/天)治疗的小肠移植动物中,移植物抗宿主病的体征,包括脾肿大和肠道黏膜结构改变,以及乳果糖与鼠李糖比率的增加均显著减轻。
移植物抗宿主病与乳果糖与鼠李糖清除率增加有关,反映宿主肠通透性增加。这种增加以及全身移植物抗宿主病的体征可通过环孢素A显著改善。乳果糖与鼠李糖清除率是一种可用于评估移植物抗宿主病肠道效应及相关肠通透性增加的非侵入性技术。